Cellenis DermaPRP vs Hyaluronic Acid Filler: Which Fits Your Treatment Goal?
Choosing between Cellenis DermaPRP and hyaluronic acid (HA) filler starts with defining what you hope to change. These treatments use different materials, and available evidence does not establish that one is a universal substitute for the other. The right questions are what each treatment is intended to address, what evidence applies to that goal, and what uncertainties and risks you should discuss with a qualified provider.
Start with the result you want.
A person hoping for more defined lip or cheek shape has a different goal from someone seeking a subtle change in fine facial texture. A third person may be concerned about loose skin. These are examples to help frame a conversation, not patient stories or automatic treatment recommendations.
One injectable should not be promised to solve all three concerns. Volume and contour, skin texture, and skin laxity are different goals. An injectable may be considered for some concerns, but it should not be assumed to tighten loose skin or produce a particular result. A careful assessment helps clarify what change is realistic to discuss and whether an injectable is a suitable option at all.
What actually goes into each treatment?
HA filler is a gel made with hyaluronic acid. Different filler products have specific characteristics and authorized uses; they are not all interchangeable. HA fillers are commonly used to add or restore volume and shape in particular facial areas, depending on the product and treatment plan.
Cellenis DermaPRP is not the same material as an HA gel. The manufacturer describes its DermaFiller as a patient’s platelet-rich plasma (PRP) used with a processed plasma-protein scaffold. That is a high-level description of the product, not independent proof of how well it works for a specific concern. It also should not be confused with ordinary liquid PRP. PRP, platelet-rich fibrin (PRF), and plasma gels can involve different preparations, so findings about one should not automatically be applied to another. The manufacturer’s product information describes the material, while clinical evidence for the branded treatment remains a separate question.
Compare goals, not marketing labels.
The table offers a starting point for a discussion, not a treatment recommendation. Exact products, areas, and goals matter.
Consideration | Hyaluronic acid filler | Cellenis DermaPRP |
|---|---|---|
Material | A formulated HA gel. Products differ. | The manufacturer describes patient-derived PRP with a processed plasma-protein scaffold. |
Proposed role | Product- and area-specific contour or volume changes. | Marketed for soft-tissue augmentation and skin-quality effects. That does not establish equivalence to a particular HA product. |
Evidence relevant to the goal | Evidence and authorized uses vary by product and treatment area. | Studies of other plasma preparations do not by themselves establish results for Cellenis. |
Timing questions | Ask when a change should be assessed and what may affect the appearance soon after treatment. | Ask the same questions, and how the specific formulation and goal affect follow-up. |
Uncertainty | Product choice and treatment area matter; results and risks are not identical across fillers. | Evidence for the exact branded product and intended use may be limited or different from studies of other preparations. |
Follow-up | Discuss review, maintenance, alternatives, and what to do if you have a concern. | Discuss review, maintenance, alternatives, and what to do if you have a concern. |
The FDA’s dermal filler information explains that approvals and authorized uses are specific to products and treatment areas. Do not assume that a product is FDA-approved for every cosmetic purpose, or that evidence for one filler applies to another. Evercare lists both HA filler and Cellenis DermaPRP/DermaFiller among its services; that confirms the treatments are listed by the practice, not that they are right for every person or goal. View Evercare’s filler information.
What do results studies really tell us?
Evidence snapshot: A small, uncontrolled study of plasma gel involving 52 women reported improvements over a short follow-up period. Because it had no comparison group and examined a plasma-gel preparation, it cannot establish that Cellenis works, how it compares with HA filler, or how long a result lasts. Read the 2019 study.
PRP studies have also reported mixed findings. In one trial, some participants reported improvements in texture and wrinkles, but blinded dermatologist assessments did not show a significant difference. Read the 2018 study. In another small trial involving PRP with microneedling, researchers did not detect an advantage over saline. Read the 2024 study.
These studies examine different preparations and approaches. They are not direct Cellenis-versus-HA trials. They therefore do not prove that Cellenis is superior to, equivalent to, or ineffective compared with HA filler. When you review a claim, ask whether the evidence studied the exact product, treatment area, and outcome you care about.
How to judge your result fairly.
Before treatment, agree with your provider on the specific change you are assessing and an appropriate follow-up date. If photos are used for comparison, consistent lighting, camera angle, and facial expression can make differences easier to judge. An immediate post-injection appearance may include swelling, so it should not be treated as proof of a lasting benefit.
There is no single timeline or downtime that applies to every product and person. Ask what follow-up is appropriate for the treatment being considered, what maintenance might involve, and how the overall treatment burden compares with alternatives. It is more useful to compare those details with your goal than to focus only on a headline price.
Natural does not mean risk-free.
Any injection can involve reactions or other risks, and the details depend on the material, product, and treatment area. The FDA warns that dermal fillers can have serious complications, including when material is unintentionally injected into a blood vessel. This is one reason to discuss product-specific risks and authorized uses with a qualified provider. There is not enough evidence here to rank Cellenis and HA filler by complication rate, and neither should be described as risk-free or guaranteed to be easy to undo.
Unusual pain, a change in vision, or concerning skin-color changes after an injection warrant immediate medical attention. Do not wait for a routine appointment if these symptoms occur.
Bring a clear treatment goal to Evercare.
Evercare Wellness & Aesthetics lists both HA filler and Cellenis DermaPRP/DermaFiller. A conversation can help clarify your goal, the precise formulation and area being considered, relevant evidence, risks, alternatives, and follow-up. Individual suitability needs to be assessed rather than assumed from a treatment name or a general description.
Sources used: FDA dermal filler information; Cellenis DermaFiller product information; Doghaim et al., 2019; Alam et al., 2018; Pincelli et al., 2024; Evercare filler services.
This article is for general education and does not replace advice from a qualified healthcare professional.
For a personalized discussion of your goals, Book an appointment with Evercare Wellness & Aesthetics.
